실제 임상현장에서의 간이식 환자 대상 Everolimus와 저용량 Tacrolimus 병용요법의 유효성 및 안전성 평가
Real-World Efficacy and Safety of Everolimus with Low Dose Tacrolimus in Liver Transplantation Recipients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Post-transplant immunosuppression with calcineurin inhibitors (CNIs) is associated with kidney function impairment while mammalian target of rapamycin (mTOR) inhibitors, such as everolimus, can be used for its renal-sparing effects. In this study, we compared the efficacy and safety of everolimus with low dose tacrolimus (EVR+Low TAC) and conventional dose tacrolimus (TAC) in liver transplantation recipients. Methods: Medical records of recipients who received liver transplantation at Seoul National University Bundang Hospital from January 1st 2009 to December 31st 2018 were retrospectively reviewed. Cohort entry date was defined as the day everolimus was initiated and tacrolimus dosage was reduced. All patients were followed up for 1 year. Indicator of efficacy was the incidence of rejection and safety was evaluated by incidence of drug adverse events including renal function. Results: Among 118 patients, there were 40 patients (33.9%) in EVR+Low TAC group. Incidence of rejection, including both biopsy proven acute rejection and clinical rejection, was similar in two groups [7.5% (n=3) vs. 6.4% (n=5), p=1.000]. Renal dysfunction was less frequent in EVR+Low TAC [17.5% (n=7) vs. 35.9% (n=28), p=0.038]. However, incidence rates of dyslipidemia, oral ulcer were more frequent in EVR+Low TAC [45.0% (n=18) vs. 21.8% (n=17), p=0.009; 15.0% (n=6) vs. 1.3% (n=1), p=0.006]. Conclusions: In terms of prevention of rejection, EVR+Low TAC was as effective as TAC and had renal-sparing effect but was associated with increased risk of dyslipidemia and oral ulcer. This study demonstrates that EVR+Low TAC could be an alternative to liver transplant recipients with nephrotoxicity after administration of conventional dose tacrolimus.
Abstract
Background: Post-transplant immunosuppression with calcineurin inhibitors (CNIs) is associated with kidney function impairment while mammalian target of rapamycin (mTOR) inhibitors, such as everolimus, can be used for its renal-sparing effects. In this study, we compared the efficacy and safety of everolimus with low dose tacrolimus (EVR+Low TAC) and conventional dose tacrolimus (TAC) in liver transplantation recipients. Methods: Medical records of recipients who received liver transplantation at Seoul National University Bundang Hospital from January 1st 2009 to December 31st 2018 were retrospectively reviewed. Cohort entry date was defined as the day everolimus was initiated and tacrolimus dosage was reduced. All patients were followed up for 1 year. Indicator of efficacy was the incidence of rejection and safety was evaluated by incidence of drug adverse events including renal function. Results: Among 118 patients, there were 40 patients (33.9%) in EVR+Low TAC group. Incidence of rejection, including both biopsy proven acute rejection and clinical rejection, was similar in two groups [7.5% (n=3) vs. 6.4% (n=5), p=1.000]. Renal dysfunction was less frequent in EVR+Low TAC [17.5% (n=7) vs. 35.9% (n=28), p=0.038]. However, incidence rates of dyslipidemia, oral ulcer were more frequent in EVR+Low TAC [45.0% (n=18) vs. 21.8% (n=17), p=0.009; 15.0% (n=6) vs. 1.3% (n=1), p=0.006]. Conclusions: In terms of prevention of rejection, EVR+Low TAC was as effective as TAC and had renal-sparing effect but was associated with increased risk of dyslipidemia and oral ulcer. This study demonstrates that EVR+Low TAC could be an alternative to liver transplant recipients with nephrotoxicity after administration of conventional dose tacrolimus.
참고문헌 (34)
- Oh CK, "Safety and efficacy of the early introduction of everolimus with reducedexposure cyclosporine a in de novo kidney recipients", Transplantation, 99(1), pp.180~186 (2015)
- Jeng LB, "Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients : 12-month results of a randomized multicenter study", Am J Transplant, 18(6), pp.1435~1446 (2018)
- Lin M, "Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients : A systematic review and meta-analysis", Clin Transplant, 31(2) (2017)
- Saliba F, "Efficacy and safety of everolimus and mycophenolic acid with early tacrolimus withdrawal after liver transplantation : A multicenter randomized trial", Am J Transplant, 17(7), pp.1843~1852 (2017)
- Cholongitas E, "Everolimus with or without mycophenolate mofetil in a liver transplantation setting : A single-center experience", Ann Gastroenterol, 31(5), pp.613~620 (2018)
- Morard I, "Long-term renal function after liver transplantation is related to calcineurin inhibitors blood levels", Clin Transplant, 20(1), pp.96~101 (2006)
- Herden U, "Early initiation of everolimus after liver transplantation : A single-center experience", Ann Transplant, 21, pp.77~85 (2016)
- Flechner SM, "Calcineurin inhibitorsparing regimens in solid organ transplantation : Focus on improving renal function and nephrotoxicity", Clin Transplant, 22(1), pp.1~15 (2008)
- Kim MS, "Clinical application of mammalian target of rapamycin inhibitor in kidney transplantation", J Korean Soc Transplant, 22(2), pp.169~176 (2008)
- Saliba F, "Renal function at two years in liver transplant patients receiving everolimus: Results of a randomized, multicenter study", Am J Transplant, 13(7), pp.1734~1745 (2013)
- Kovarik JM, "Everolimus therapeutic concentration range defined from a prospective trial with reducedexposure cyclosporine in de novo kidney transplantation", Ther Drug Monit, 26(5), pp.499~505 (2004)
- Lorber MI, "Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter, phase iii study", Transplantation, 80(2), pp.244~252 (2005)
- Tedesco-Silva H, Jr., "12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients", Transpl Int, 20(1), pp.27~36 (2007)
- Vitko S, "Everolimus(certican)12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients", Transplantation, 78(10), pp.1532~1540 (2004)
- Vitko S, "Everolimus with optimized cyclosporine dosing in renal transplant recipients : 6-month safety and efficacy results of two randomized studies", Am J Transplant, 4(4), pp.626~635 (2004)
- "Certican 0.5mg(everolimus)"[URL]
- De Simone P, "Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients : A randomized controlled trial", Am J Transplant, 12(11), pp.3008~3020 (2012)
- 이슬이, "간 이식 환자에서의 Everolimus 사용 현황 분석", 병원약사회지, 35(2), pp.135~142 (2018), 한국병원약사회[DOI]
- Ormonde DG, "Banff schema for grading liver allograft rejection : Utility in clinical practice", Liver Transpl Surg, 5(4), pp.261~268 (1999)
- "Prograf® 2021"[URL]
- Fischer L, "A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation--PROTECT", Am J Transplant, 12(7), pp.1855~1865 (2012)
- Montalti R, "Early use of mammalian target of rapamycin inhibitors is an independent risk factor for incisional hernia development after liver transplantation", Liver Transpl, 18(2), pp.188~194 (2012)
- Jeng LB, "Experience of using everolimus in the early stage of living donor liver transplantation", Transplant Proc, 46(3), pp.744~748 (2014)
- Fung J, "Rapamycin: Friend, foe, or misunderstood?", Liver Transpl, 9(5), pp.469~472 (2003)
- Porta C, "Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma", Eur J Cancer, 47(9), pp.1287~1298 (2011)
- Kaplan B, "Strategies for the management of adverse events associated with mtor inhibitors", Transplant Rev(Orlando), 28(3), pp.126~133 (2014)
- Fraenkel M, "Mtor inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes", Diabetes, 57(4), pp.945~957 (2008)
- Houde VP, "Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue", Diabetes, 59(6), pp.1338~1348 (2010)
- Engels EA, "Spectrum of cancer risk among us solid organ transplant recipients", JAMA, 306(17), pp.1891~1901 (2011)
- Acuna SA, "Cancer mortality among recipients of solid-organ transplantation in ontario, canada", JAMA Oncol, 2(4), pp.463~469 (2016)
- Holdaas H, "Everolimus and malignancy after solid organ transplantation : A clinical update", J Transplant, 2016, pp.4369574~ (2016)
- Guan TW, "Efficacy and safety of everolimus treatment on liver transplant recipients : A meta-analysis", Eur J Clin Invest, 49(12), pp.e13179~ (2019)
- Holdaas H, "mTor inhibitors and dyslipidemia in transplant recipients: A cause for concern?", Transplant Rev (Orlando), 29(2), pp.93~102 (2015)
- Pereira MJ, "The immunosuppressive agents rapamycin, cyclosporin a and tacrolimus increase lipolysis, inhibit lipid storage and alter expression of genes involved in lipid metabolism in human adipose tissue", Mol Cell Endocrinol, 365(2), pp.260~269 (2013)